Electrophysiologic testing for diagnostic evaluation and risk stratification in patients with suspected cardiac sarcoidosis with preserved left and right ventricular systolic function
- 30 June 2019
- journal article
- research article
- Published by Wiley in Journal of Cardiovascular Electrophysiology
- Vol. 30 (10) , 1939-1948
Abstract
Introduction: While cardiac sarcoidosis (CS) carries a risk of ventricular arrhythmias (VAs) and sudden cardiac death (SCD), risk stratification of patients with CS and preserved left ventricular/right ventricular (LV/RV) systolic function remains challenging. We sought to evaluate the role of electrophysiologic testing and programmed electrical stimulation of the ventricle (EPS) in patients with suspected CS with preserved ventricular function.Methods: One hundred twenty consecutive patients with biopsy‐proven extracardiac sarcoidosis and preserved LV/RV systolic function underwent EPS. All patients had either probable CS defined by an abnormal cardiac positron emission tomography or cardiac magnetic resonance imaging, or possible CS with normal advanced imaging but abnormal echocardiogram (ECG), SAECG, Holter, or clinical factors. Patients were followed for 4.5 ± 2.6 years for SCD and VAs.Results: Seven of 120 patients (6%) had inducible ventricular tachycardia (VT) with EPS and received an implantable cardioverter defibrillator (ICD). Three patients (43%) with positive EPS later had ICD therapies for VAs. Kaplan‐Meier analysis stratified by EPS demonstrated a significant difference in freedom from VAs and SCD (P = 0.009), though this finding was driven entirely by patients within the cohort with probable CS (P = 0.018, n = 69). One patient with possible CS and negative EPS had unrecognized progression of the disease and unexplained death with evidence of CS at autopsy.Conclusions: EPS is useful in the risk stratification of patients with probable CS with preserved LV and RV function. A positive EPS was associated with VAs. While a negative EPS appeared to confer low risk, close follow‐up is needed as EPS cannot predict fatal VAs related to new cardiac involvement or disease progression.Keywords
This publication has 36 references indexed in Scilit:
- Efficacy and safety of implantable cardiac defibrillators for treatment of ventricular arrhythmias in patients with cardiac sarcoidosisEP Europace, 2012
- Diagnostic Utility of Signal-Averaged Electrocardiography for Detection of Cardiac SarcoidosisAnnals of Noninvasive Electrocardiology, 2011
- Endocardial unipolar voltage mapping to identify epicardial substrate in arrhythmogenic right ventricular cardiomyopathy/dysplasiaHeart Rhythm, 2011
- Classification of the cardiomyopathies: a position statement from the european society of cardiology working group on myocardial and pericardial diseasesEuropean Heart Journal, 2007
- ACC/AHA/ESC 2006 Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac DeathJACC, 2006
- Usefulness of Programmed Ventricular Stimulation in Predicting Future Arrhythmic Events in Patients With Cardiac SarcoidosisThe American Journal of Cardiology, 2005
- A Randomized Study of the Prevention of Sudden Death in Patients with Coronary Artery DiseaseNew England Journal of Medicine, 1999
- Guidelines for the study of familial dilated cardiomyopathiesEuropean Heart Journal, 1999
- Sustained ventricular tachycardia associated with sarcoidosis: Assessment of the underlying cardiac anatomy and the prospective utility of programmed ventricular stimulation, drug therapy and an implantable antitachycardia deviceJACC, 1991
- Cardiac sarcoid: a clinicopathologic study of 84 unselected patients with systemic sarcoidosis.Circulation, 1978